4 completed, 3 recruiting, 2 not yet recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow inapplicable: new trials by email Literature Review of inapplicable trials Research Report on inapplicable
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on the Correlation Between Metabolomics and Anxiety and Depression in Bronchiectasis inapplicable - Bronchiectasis | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 300 | 2025-12-20 | 2025-12-18 | |
| AI-based Model for Rehabilitation Engagement and Motor Performance Evaluation in Pediatric Patients Inapplicable - Neuromotor Impairments | Completed | IRCCS Eugenio Medea | 31 | 2025-06-09 | 2026-06-25 | |
| A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks Inapplicable - Hereditary Angioedema | Completed | KalVista Pharmaceuticals, Ltd. | 88 | 2025-04-21 | 2026-01-13 | |
| Exploring the Effectiveness and Factors Affecting the Collection of Single Nucleated Cells From Different Volunteers inapplicable - Observational Study | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2024-05-01 | 2024-04-12 | |
| Study on Disease Progression and Nutritional Status in Bronchiectasis inapplicable - Bronchiectasis | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 300 | 2024-04-15 | 2025-09-25 | |
| Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19) DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin) - Non-small Cell Lung Cancer | Phase 1 | Completed | Dizal Pharmaceuticals | 25 | 2023-07-31 | 2024-12-13 |
| A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) DZD9008+AZD4205 - Non-small Cell Lung Cancer | Phase 2 | Completed | Dizal Pharmaceuticals | 30 | 2023-06-01 | 2026-10-22 |
| DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) DZD9008 plus Bevacizumab - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Dizal Pharmaceuticals | 60 | 2023-02-15 | 2025-06-19 |
| Observational Study to Observe Variations of Gait Parameters in Patients With Neuromuscular Diseases inapplicable - Muscular Dystrophies, Myopathies | Recruiting | IRCCS Eugenio Medea | 120 | 2017-10-27 | 2026-01-20 |
Carcinoma, Non-Small-Cell Lung (3) · Bronchiectasis (2) · Angioedemas, Hereditary (1) · Anxiety Disorders (1) · Charcot-Marie-Tooth Disease (1) · Depression (1) · Muscular Atrophy, Spinal (1) · Muscular Diseases (1) · Muscular Dystrophies (1)
Dizal Pharmaceuticals (3) · IRCCS Eugenio Medea (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · KalVista Pharmaceuticals, Ltd. (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)
China (5) · Italy (2) · United States (1)
Xiaorong Wang (1) · Zhen Wang (1)
PMID 28842946, PMID 28889110, PMID 30545985, PMID 34579692, PMID 36669778, PMID 41678415